Clinical outcomes of EGFR +/ METamp+ vs. EGFR +/ METamp‐ untreated patients with advanced non‐small cell lung cancer

BACKGROUND: MET dysregulation has been implicated in the development of primary and secondary resistance to EGFR tyrosine kinase inhibitor (TKI) therapy. However, the clinicopathological characteristics and outcomes of patients harboring EGFR‐sensitive mutations and de novo MET amplifications still...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Kai‐Cheng, Su, Jun‐Wei, Xie, Zhi, Wang, Han‐Min, Fang, Mei‐Mei, Li, Wen‐Feng, Chen, Yu‐Qing, Guan, Xu‐Hui, Su, Jian, Yan, Hong‐Hong, Zhang, Xu‐Chao, Tu, Hai‐Yan, Zhou, Qing, Chen, Hua‐Jun, Wu, Yi‐Long, Yang, Jin‐Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161327/
https://www.ncbi.nlm.nih.gov/pubmed/35437920
http://dx.doi.org/10.1111/1759-7714.14429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161327/
https://www.ncbi.nlm.nih.gov/pubmed/35437920
http://dx.doi.org/10.1111/1759-7714.14429

Ejemplares similares